BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Exarafenib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Exarafenib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04913285-2577@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Exarafenib: Phase 1 readout est. (NCT04913285)
DESCRIPTION:Exarafenib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Po
 sitive Solid Tumors\nEstimated primary completion: 30 November 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/exarafenib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04913285
URL:https://assetmemo.bio/drug/exarafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
